Anthera Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ANTH)

$1.55 0.06 (4.03 %)
(As of 12/17/2017 04:00 PM ET)
Previous Close$1.55
Today's Range$1.46 - $1.58
52-Week Range$1.20 - $17.04
Volume243,954 shs
Average Volume374,095 shs
Market Capitalization$21.47 million
P/E RatioN/A
Dividend YieldN/A
Beta2.71

About Anthera Pharmaceuticals (NASDAQ:ANTH)

Anthera Pharmaceuticals logoAnthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

Receive ANTH News and Ratings via Email

Sign-up to receive the latest news and ratings for ANTH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ANTH
CUSIPN/A
Phone510-856-5600

Debt

Debt-to-Equity RatioN/A
Current Ratio1.97%
Quick Ratio1.97%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$140,000.00
Price / Sales153.34
Cash FlowN/A
Price / CashN/A
Book Value$0.67 per share
Price / Book2.31

Profitability

Trailing EPS($5.46)
Net Income$-55,520,000.00
Net MarginsN/A
Return on Equity-1,497.08%
Return on Assets-224.18%

Miscellaneous

Employees33
Outstanding Shares13,850,000

Anthera Pharmaceuticals (NASDAQ:ANTH) Frequently Asked Questions

What is Anthera Pharmaceuticals' stock symbol?

Anthera Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANTH."

When did Anthera Pharmaceuticals' stock split? How did Anthera Pharmaceuticals' stock split work?

Anthera Pharmaceuticals's stock reverse split before market open on Monday, May 1st 2017. The 1-8 reverse split was announced on Friday, April 28th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 28th 2017. An investor that had 100 shares of Anthera Pharmaceuticals stock prior to the reverse split would have 13 shares after the split.

How were Anthera Pharmaceuticals' earnings last quarter?

Anthera Pharmaceuticals Inc (NASDAQ:ANTH) announced its earnings results on Monday, November, 6th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.90) by $0.32. During the same period in the previous year, the company earned ($4.85) earnings per share. View Anthera Pharmaceuticals' Earnings History.

When will Anthera Pharmaceuticals make its next earnings announcement?

Anthera Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for Anthera Pharmaceuticals.

Where is Anthera Pharmaceuticals' stock going? Where will Anthera Pharmaceuticals' stock price be in 2017?

5 equities research analysts have issued 12 month price objectives for Anthera Pharmaceuticals' shares. Their forecasts range from $1.75 to $10.80. On average, they expect Anthera Pharmaceuticals' share price to reach $5.89 in the next twelve months. View Analyst Ratings for Anthera Pharmaceuticals.

What are Wall Street analysts saying about Anthera Pharmaceuticals stock?

Here are some recent quotes from research analysts about Anthera Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company's clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren's Syndrome, Graves' Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California. " (10/24/2017)
  • 2. Jefferies Group LLC analysts commented, "Following narrow miss in Sollpura SOLUTION study in late 2016, ANTH has included key learnings into the Ph. III RESULT study, to start soon and data by early 2018. Decision to discontinue B-mod in lupus is not surprising due to negative CHABLIS data in Q4 2016 and conserves cash. With $21M in cash and two ATMs, ANTH is positioned to fund operations through RESULT data. We expect shares to remain range-bound NT due to few 2017 data catalysts. Lower PT to $0.80." (3/6/2017)

Are investors shorting Anthera Pharmaceuticals?

Anthera Pharmaceuticals saw a decrease in short interest in November. As of November 30th, there was short interest totalling 1,108,395 shares, a decrease of 28.5% from the November 15th total of 1,549,997 shares. Based on an average daily volume of 417,516 shares, the days-to-cover ratio is presently 2.7 days. Currently, 8.3% of the company's shares are sold short.

Who are some of Anthera Pharmaceuticals' key competitors?

Who are Anthera Pharmaceuticals' key executives?

Anthera Pharmaceuticals' management team includes the folowing people:

  • Paul F. Truex, Executive Chairman of the Board
  • Craig Thompson, President, Chief Executive Officer, Chief Operating Officer, Director (Age 50)
  • May Liu, Senior Vice President - Finance and Administration, Principal Accounting Officer (Age 39)
  • William R. Shanahan Jr. M.D. J.D., Chief Medical Officer (Age 68)
  • Brent Furse, Director (Age 47)
  • Christopher S. Henney Ph.D., Independent Director (Age 76)
  • Brian R. Mueller, Independent Director (Age 43)
  • Philip T Sager, Independent Director (Age 59)
  • David E. Thompson, Independent Director (Age 67)

Who owns Anthera Pharmaceuticals stock?

Anthera Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Wedbush Securities Inc. (0.68%). Company insiders that own Anthera Pharmaceuticals stock include John Craig Thompson and Paul F Truex. View Institutional Ownership Trends for Anthera Pharmaceuticals.

Who bought Anthera Pharmaceuticals stock? Who is buying Anthera Pharmaceuticals stock?

Anthera Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have bought Anthera Pharmaceuticals stock in the last two years include John Craig Thompson and Paul F Truex. View Insider Buying and Selling for Anthera Pharmaceuticals.

How do I buy Anthera Pharmaceuticals stock?

Shares of Anthera Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anthera Pharmaceuticals' stock price today?

One share of Anthera Pharmaceuticals stock can currently be purchased for approximately $1.55.

How big of a company is Anthera Pharmaceuticals?

Anthera Pharmaceuticals has a market capitalization of $21.47 million and generates $140,000.00 in revenue each year. The biopharmaceutical company earns $-55,520,000.00 in net income (profit) each year or ($5.46) on an earnings per share basis. Anthera Pharmaceuticals employs 33 workers across the globe.

How can I contact Anthera Pharmaceuticals?

Anthera Pharmaceuticals' mailing address is 25801 INDUSTRIAL BOULEVARD SUITE B, HAYWARD CA, 94545. The biopharmaceutical company can be reached via phone at 510-856-5600.


MarketBeat Community Rating for Anthera Pharmaceuticals (ANTH)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  197 (Vote Outperform)
Underperform Votes:  188 (Vote Underperform)
Total Votes:  385
MarketBeat's community ratings are surveys of what our community members think about Anthera Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Anthera Pharmaceuticals (NASDAQ:ANTH) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.332.332.332.33
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.89$5.89$11.14$26.61
Price Target Upside: 346.02% upside346.02% upside776.97% upside1,155.19% upside

Anthera Pharmaceuticals (NASDAQ:ANTH) Consensus Price Target History

Price Target History for Anthera Pharmaceuticals (NASDAQ:ANTH)

Anthera Pharmaceuticals (NASDAQ:ANTH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/19/2017HC WainwrightReiterated RatingBuy$3.00MediumView Rating Details
8/11/2017Jefferies GroupReiterated RatingHold$2.25 -> $1.75LowView Rating Details
12/29/2016Piper Jaffray CompaniesLower Price TargetOverweight$56.00 -> $10.80N/AView Rating Details
12/29/2016CitigroupDowngradeBuy -> NeutralN/AView Rating Details
12/28/2016SunTrust BanksDowngradeBuy -> Hold$48.00 -> $8.00N/AView Rating Details
6/20/2016FBR & CoReiterated RatingHoldN/AView Rating Details
(Data available from 12/17/2015 forward)

Earnings

Anthera Pharmaceuticals (NASDAQ:ANTH) Earnings History and Estimates Chart

Earnings by Quarter for Anthera Pharmaceuticals (NASDAQ:ANTH)

Anthera Pharmaceuticals (NASDAQ ANTH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018($0.82)N/AView Earnings Details
11/6/2017Q3 2017($0.90)($0.58)ViewN/AView Earnings Details
8/9/2017Q2 2017($1.09)$0.03ViewN/AView Earnings Details
5/10/2017Q1 2017($1.47)($2.03)ViewN/AView Earnings Details
2/27/2017Q4 2016($3.25)($2.88)$0.10 millionViewN/AView Earnings Details
11/4/2016Q3($3.04)($4.88)$0.18 millionViewN/AView Earnings Details
8/9/2016Q2($2.48)($2.80)$0.15 millionViewN/AView Earnings Details
5/9/2016Q1($2.24)($2.32)$0.15 millionViewN/AView Earnings Details
3/10/2016Q4($2.24)($1.44)$0.31 million$1.92 millionViewN/AView Earnings Details
11/6/2015Q315($2.08)($2.32)$0.31 million$0.73 millionViewN/AView Earnings Details
8/10/2015Q2($2.24)($2.00)$0.29 millionViewN/AView Earnings Details
5/11/2015Q115($2.48)($2.24)$0.25 millionViewN/AView Earnings Details
3/16/2015Q4 2014($2.64)($2.56)ViewN/AView Earnings Details
11/14/2014Q3 2014($2.88)($2.48)ViewN/AView Earnings Details
7/28/2014Q2 2014($3.92)($2.72)ViewN/AView Earnings Details
5/13/2014Q114($4.48)($3.12)ViewN/AView Earnings Details
3/12/2014($3.76)($3.84)ViewN/AView Earnings Details
3/26/2013Q412($1.20)($0.88)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Anthera Pharmaceuticals (NASDAQ:ANTH) Earnings Estimates

2017 EPS Consensus Estimate: ($3.30)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.36)($0.16)($0.26)
Q2 20172($1.08)($1.06)($1.07)
Q3 20172($1.24)($0.95)($1.10)
Q4 20172($1.03)($0.71)($0.87)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Anthera Pharmaceuticals (NASDAQ:ANTH)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Anthera Pharmaceuticals (NASDAQ ANTH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.08%
Institutional Ownership Percentage: 16.24%
Insider Trades by Quarter for Anthera Pharmaceuticals (NASDAQ:ANTH)
Institutional Ownership by Quarter for Anthera Pharmaceuticals (NASDAQ:ANTH)

Anthera Pharmaceuticals (NASDAQ ANTH) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/20/2017John Craig ThompsonCEOBuy8,550$1.32$11,286.00View SEC Filing  
9/7/2017John Craig ThompsonCEOBuy10,400$1.43$14,872.00View SEC Filing  
9/7/2017Paul F TruexDirectorBuy5,000$1.34$6,700.00View SEC Filing  
11/13/2015Colin HislopinsiderSell12,500$5.31$66,375.00View SEC Filing  
11/11/2015Colin HislopInsiderSell5,000$5.38$26,900.00View SEC Filing  
10/12/2015Debra OdinkCTOSell1,205$6.15$7,410.75View SEC Filing  
6/24/2013David E ThompsonDirectorBuy12,500$0.53$6,625.00View SEC Filing  
5/31/2013Bogdan DziurzynskiDirectorBuy1,250$0.59$737.50View SEC Filing  
1/30/2013Orbimed Advisors LlcDirectorBuy712,500$0.66$470,250.00View SEC Filing  
1/25/2013Orbimed Advisors LlcDirectorBuy220,250$0.65$143,162.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Anthera Pharmaceuticals (NASDAQ ANTH) News Headlines

Source:
DateHeadline
Anthera Pharmaceuticals, Inc. (ANTH) Short Interest UpdateAnthera Pharmaceuticals, Inc. (ANTH) Short Interest Update
www.americanbankingnews.com - December 16 at 2:08 AM
Anthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analysis in the Phase 3 RESULT Clinical ... - GlobeNewswire (press release)Anthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analysis in the Phase 3 RESULT Clinical ... - GlobeNewswire (press release)
globenewswire.com - December 12 at 5:37 AM
Anthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analysis in the Phase 3 RESULT Clinical Study of SollpuraAnthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura
finance.yahoo.com - December 11 at 3:15 PM
Anthera Pharmaceuticals, Inc. (ANTH) Given Average Rating of "Hold" by BrokeragesAnthera Pharmaceuticals, Inc. (ANTH) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - December 8 at 9:36 PM
Zacks: Analysts Expect Anthera Pharmaceuticals, Inc. (ANTH) Will Post Earnings of -$0.87 Per ShareZacks: Analysts Expect Anthera Pharmaceuticals, Inc. (ANTH) Will Post Earnings of -$0.87 Per Share
www.americanbankingnews.com - December 3 at 8:14 AM
Want To Invest In Anthera Pharmaceuticals Inc (ANTH)? Here’s How It Performed LatelyWant To Invest In Anthera Pharmaceuticals Inc (ANTH)? Here’s How It Performed Lately
finance.yahoo.com - November 30 at 5:32 AM
Anthera Pharmaceuticals: Buy The Dip - Seeking AlphaAnthera Pharmaceuticals: Buy The Dip - Seeking Alpha
seekingalpha.com - November 29 at 5:31 AM
Best Growth Stocks To BuyBest Growth Stocks To Buy
finance.yahoo.com - November 25 at 3:28 PM
Anthera Pharma (ANTH) Receives Nasdaq Listing Determination Notice, Plans AppealAnthera Pharma (ANTH) Receives Nasdaq Listing Determination Notice, Plans Appeal
www.streetinsider.com - November 18 at 1:41 AM
Jefferies Group Equities Analysts Lift Earnings Estimates for Anthera Pharmaceuticals, Inc. (ANTH)Jefferies Group Equities Analysts Lift Earnings Estimates for Anthera Pharmaceuticals, Inc. (ANTH)
www.americanbankingnews.com - November 17 at 9:44 PM
Anthera Pharmaceuticals Announces Receipt of Nasdaq Listing Determination Notice and Plans Appeal - GlobeNewswire (press release)Anthera Pharmaceuticals Announces Receipt of Nasdaq Listing Determination Notice and Plans Appeal - GlobeNewswire (press release)
globenewswire.com - November 17 at 8:41 PM
Anthera Pharmaceuticals Announces Receipt of Nasdaq Listing Determination Notice and Plans AppealAnthera Pharmaceuticals Announces Receipt of Nasdaq Listing Determination Notice and Plans Appeal
finance.yahoo.com - November 17 at 8:41 PM
Anthera Pharmaceuticals: Run Up Into Q1 Data - Seeking AlphaAnthera Pharmaceuticals: Run Up Into Q1 Data - Seeking Alpha
seekingalpha.com - November 16 at 11:14 AM
 Brokerages Expect Anthera Pharmaceuticals, Inc. (ANTH) Will Post Earnings of -$0.87 Per Share Brokerages Expect Anthera Pharmaceuticals, Inc. (ANTH) Will Post Earnings of -$0.87 Per Share
www.americanbankingnews.com - November 14 at 9:20 PM
BRIEF-Anthera Pharmaceuticals files for resale of up to 28.6 million shares of cos common stockBRIEF-Anthera Pharmaceuticals files for resale of up to 28.6 million shares of co's common stock
www.reuters.com - November 14 at 2:27 AM
Anthera Pharmaceuticals, Inc. (ANTH) Receives Average Rating of "Hold" from AnalystsAnthera Pharmaceuticals, Inc. (ANTH) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - November 13 at 9:34 PM
Anthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 RESULT Clinical Study of Sollpura - GlobeNewswire (press release)Anthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 RESULT Clinical Study of Sollpura - GlobeNewswire (press release)
globenewswire.com - November 10 at 7:10 PM
Anthera Pharma (ANTH) Completes Recruitment in Phase 3 RESULT Clinical Study of SollpuraAnthera Pharma (ANTH) Completes Recruitment in Phase 3 RESULT Clinical Study of Sollpura
www.streetinsider.com - November 10 at 2:10 PM
Anthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 RESULT Clinical Study of SollpuraAnthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 RESULT Clinical Study of Sollpura
finance.yahoo.com - November 9 at 5:00 PM
FY2017 Earnings Forecast for Anthera Pharmaceuticals, Inc. (ANTH) Issued By SunTrust BanksFY2017 Earnings Forecast for Anthera Pharmaceuticals, Inc. (ANTH) Issued By SunTrust Banks
www.americanbankingnews.com - November 9 at 8:38 AM
Anthera Pharmaceuticals Provides Business Update and Reports 2017 Third Quarter Financial Results - GlobeNewswire (press release)Anthera Pharmaceuticals Provides Business Update and Reports 2017 Third Quarter Financial Results - GlobeNewswire (press release)
globenewswire.com - November 7 at 2:58 AM
Anthera Pharmaceuticals Provides Business Update and Reports 2017 Third Quarter Financial ResultsAnthera Pharmaceuticals Provides Business Update and Reports 2017 Third Quarter Financial Results
finance.yahoo.com - November 6 at 4:41 PM
Anthera reports 3Q lossAnthera reports 3Q loss
finance.yahoo.com - November 6 at 4:41 PM
Who Are The Major Shareholders Of Anthera Pharmaceuticals Inc (ANTH)?Who Are The Major Shareholders Of Anthera Pharmaceuticals Inc (ANTH)?
finance.yahoo.com - November 6 at 4:41 PM
Anthera Pharmaceuticals, Inc. (ANTH) Announces  Earnings ResultsAnthera Pharmaceuticals, Inc. (ANTH) Announces Earnings Results
www.americanbankingnews.com - November 6 at 10:08 AM
Anthera Pharmaceuticals Announces Presentation of Blisibimod Data at the American College of Rheumatology ... - GlobeNewswire (press release)Anthera Pharmaceuticals Announces Presentation of Blisibimod Data at the American College of Rheumatology ... - GlobeNewswire (press release)
globenewswire.com - November 6 at 2:01 AM
BRIEF-Armistice Capital reports 5.6 percent passive stake in Anthera PharmaBRIEF-Armistice Capital reports 5.6 percent passive stake in Anthera Pharma
www.reuters.com - November 3 at 9:07 PM
Anthera Pharmaceuticals Announces Presentations of Sollpura Data at the North American Cystic Fibrosis Conference - NasdaqAnthera Pharmaceuticals Announces Presentations of Sollpura Data at the North American Cystic Fibrosis Conference - Nasdaq
www.nasdaq.com - November 3 at 4:03 PM
Anthera Pharmaceuticals Announces Presentations of Sollpura Data at the North American Cystic Fibrosis Conference - GlobeNewswire (press release)Anthera Pharmaceuticals Announces Presentations of Sollpura Data at the North American Cystic Fibrosis Conference - GlobeNewswire (press release)
globenewswire.com - November 2 at 9:23 PM
Anthera Pharmaceuticals Announces Presentation of Blisibimod Lupus Research at the American Society of ... - GlobeNewswire (press release)Anthera Pharmaceuticals Announces Presentation of Blisibimod Lupus Research at the American Society of ... - GlobeNewswire (press release)
globenewswire.com - November 1 at 9:30 PM
Anthera Pharmaceuticals Announces Presentation of Blisibimod Lupus Research at the American Society of Nephrology Annual MeetingAnthera Pharmaceuticals Announces Presentation of Blisibimod Lupus Research at the American Society of Nephrology Annual Meeting
finance.yahoo.com - November 1 at 9:30 PM
Anthera Pharmaceuticals, Inc. (ANTH) to Release Quarterly Earnings on MondayAnthera Pharmaceuticals, Inc. (ANTH) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 12:30 PM
BRIEF-Anthera Pharmaceuticals announces pricing of $15 mln private placement offeringBRIEF-Anthera Pharmaceuticals announces pricing of $15 mln private placement offering
www.reuters.com - October 24 at 10:40 PM
Anthera Pharma (ANTH) Prices $15M Private Placement of Common Stock, WarrantsAnthera Pharma (ANTH) Prices $15M Private Placement of Common Stock, Warrants
www.streetinsider.com - October 24 at 10:40 PM
Health Care Sector Update for 10/24/2017: ANTH,PTIE,IMDZ - NasdaqHealth Care Sector Update for 10/24/2017: ANTH,PTIE,IMDZ - Nasdaq
www.nasdaq.com - October 24 at 5:37 PM
33 Stocks Moving In Tuesdays Mid-Day Session - Benzinga33 Stocks Moving In Tuesday's Mid-Day Session - Benzinga
www.benzinga.com - October 24 at 5:37 PM
Anthera Pharmaceuticals Announces Pricing of $15 Million Private Placement Offering - GlobeNewswire (press release)Anthera Pharmaceuticals Announces Pricing of $15 Million Private Placement Offering - GlobeNewswire (press release)
globenewswire.com - October 24 at 5:37 PM
Anthera Pharmaceuticals Announces Pricing of $15 Million Private Placement OfferingAnthera Pharmaceuticals Announces Pricing of $15 Million Private Placement Offering
finance.yahoo.com - October 24 at 5:37 PM
Anthera Pharmaceuticals, Inc. (ANTH) Lowered to Hold at Zacks Investment ResearchAnthera Pharmaceuticals, Inc. (ANTH) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - October 24 at 5:28 PM
Anthera Pharmaceuticals Inc (ANTH) Receives Consensus Recommendation of "Hold" from BrokeragesAnthera Pharmaceuticals Inc (ANTH) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - October 19 at 8:46 PM
Is There Now An Opportunity In Anthera Pharmaceuticals Inc (ANTH)?Is There Now An Opportunity In Anthera Pharmaceuticals Inc (ANTH)?
finance.yahoo.com - October 17 at 4:46 PM
Anthera Pharmaceuticals, Inc. (ANTH) Upgraded at Zacks Investment ResearchAnthera Pharmaceuticals, Inc. (ANTH) Upgraded at Zacks Investment Research
www.americanbankingnews.com - October 10 at 8:24 PM
Todays Research Reports on Trending Tickers: Anthera Pharmaceuticals and NewLink GeneticsToday's Research Reports on Trending Tickers: Anthera Pharmaceuticals and NewLink Genetics
finance.yahoo.com - October 4 at 2:22 PM
biOasis Appoints Christopher P. Lowe, M.B.A. as Chief Financial Officer and Board AdvisorbiOasis Appoints Christopher P. Lowe, M.B.A. as Chief Financial Officer and Board Advisor
www.businesswire.com - October 2 at 8:27 AM
Anthera Pharmaceuticals, Inc. (ANTH) Receives Consensus Recommendation of "Hold" from AnalystsAnthera Pharmaceuticals, Inc. (ANTH) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - September 24 at 8:34 PM
Anthera Pharmaceuticals (ANTH) vs. Its Peers Head to Head ComparisonAnthera Pharmaceuticals (ANTH) vs. Its Peers Head to Head Comparison
www.americanbankingnews.com - September 24 at 8:12 PM
Anthera Pharmaceuticals, Inc. (ANTH) CEO Purchases $11,286.00 in StockAnthera Pharmaceuticals, Inc. (ANTH) CEO Purchases $11,286.00 in Stock
www.americanbankingnews.com - September 20 at 10:22 PM
Anthera Pharmaceuticals (ANTH) "Buy" Rating Reaffirmed at HC WainwrightAnthera Pharmaceuticals' (ANTH) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - September 19 at 3:52 PM
Anthera Pharmaceuticals, Inc. (ANTH) Expected to Announce Earnings of -$0.90 Per ShareAnthera Pharmaceuticals, Inc. (ANTH) Expected to Announce Earnings of -$0.90 Per Share
www.americanbankingnews.com - September 17 at 4:20 PM
BRIEF-Anthera Pharma surpasses 50 pct milestone for screening of patients in result phase 3 clinical study of Sollpura in cystic fibrosisBRIEF-Anthera Pharma surpasses 50 pct milestone for screening of patients in result phase 3 clinical study of Sollpura in cystic fibrosis
www.reuters.com - September 8 at 4:19 PM

SEC Filings

Anthera Pharmaceuticals (NASDAQ:ANTH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Anthera Pharmaceuticals (NASDAQ:ANTH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Anthera Pharmaceuticals (NASDAQ ANTH) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.